Chimeric Therapeutics (ASX:CHM) said that the University of Chicago Medicine will enroll patients in its multi-center phase one/two clinical trial for its anti-CDH17 chimeric antigen receptor T-cell therapy, according to a Monday Australian bourse filing.
The trial is a two-stage study to determine a recommended phase two dose of CHM CDH17 and evaluate its safety and objective response rate in patients with advanced colorectal cancer, gastric cancer, and intestinal neuroendocrine tumors.
CHM CDH17 is a CAR T-cell therapy, a type of immunotherapy, that targets CDH17, a cancer target associated with poor prognosis and metastases in the most common gastrointestinal tumors, the filing said.
The first phase of the study is expected to enroll 15 patients.
Its shares rose 14% on market close.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。